Biogen will present Phase 2 CELIA data on diranersen (BIIB080), an antisense oligonucleotide designed to reduce production of tau protein, at the CTAD conference in Boston. The trial enrolled 416 people with mild cognitive impairment or mild Alzheimer's dementia, none previously treated with anti-amyloid therapy, using intrathecal dosing over 18 months with cognitive change measured by CDR-SB at week 76. Alongside 96-week extension data, the presentations mark a shift toward upstream suppression of a second core pathology rather than clearance of amyloid alone.
Key Points
- Diranersen reduces tau production upstream rather than clearing deposits
- Phase 2 CELIA enrolled 416 anti-amyloid-naive patients, intrathecal dosing
- 96-week extension, tau biomarker and amyloid PET data presented
Longevity Analysis
Reducing the synthesis of a damaging protein is a different strategic category from removing it after it accumulates, and the distinction matters for any system where clearance capacity declines with age. Tau pathology tracks more closely with nerve cell damage and cognitive trajectory than amyloid burden does, which makes tau biomarkers a more direct readout of what the aging brain is actually experiencing. The pairing of upstream suppression with downstream clearance in a single development portfolio reflects a broader principle: interference removed early is less costly than damage reversed late.
Original published by Longevity.Technology, by Kyle Umipig.